• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

P.E.T.Net pharmaceuticals licenses technology

Article

Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use

Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use the technology to develop its own diagnostic tests, as well as to participate in research partnerships with pharmaceutical companies. The tests being developed will utilize positron-emitting molecular probes specific to the plaques and neural tangles associated with Alzheimer’s disease.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.